Insider Selling: Vor Biopharma (NASDAQ:VOR) Director Sells 151,803 Shares of Stock

Key Points

• Ra Capital Management, L.P. sold 151,803 shares of Vor Biopharma stock on October 16th, significantly reducing their ownership by 72.38% and total transaction value of approximately $4.47 million.
• Vor Biopharma's stock has experienced a recent decline, trading down 0.2% to $29.00, with a current market capitalization of $198.65 million and a twelve-month range between $2.62 and $65.80.
• The company's latest earnings report showed a loss of ($43.60) earnings per share, missing analysts' estimates significantly, while institutional investors own 97.29% of the company's stock.

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) Director Ra Capital Management, L.P. sold 151,803 shares of the stock in a transaction that occurred on Thursday, October 16th. The shares were sold at an average price of $29.45, for a total value of $4,470,598.35. Following the completion of the sale, the director directly owned 57,920 shares of the company's stock, valued at $1,705,744. The trade was a 72.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Friday, October 17th, Ra Capital Management, L.P. sold 260,859 shares of Vor Biopharma stock. The shares were sold at an average price of $29.39, for a total transaction of $7,666,646.01.
• On Wednesday, October 15th, Ra Capital Management, L.P. sold 51,363 shares of Vor Biopharma stock. The stock was sold at an average price of $30.55, for a total transaction of $1,569,139.65.

Vor Biopharma Trading Down 0.2%

NASDAQ VOR traded down $0.06 during trading on Friday, reaching $29.00. The company's stock had a trading volume of 613,740 shares, compared to its average volume of 395,121. The business's fifty day moving average is $36.55. Vor Biopharma Inc. has a twelve month low of $2.62 and a twelve month high of $65.80. The firm has a market capitalization of $198.65 million, a price-to-earnings ratio of -0.11 and a beta of 2.07.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($43.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($11.40) by ($32.20).

Institutional Trading of Vor Biopharma

Large investors have recently bought and sold shares of the company. XTX Topco Ltd acquired a new position in shares of Vor Biopharma during the 2nd quarter worth $66,000. Money Concepts Capital Corp increased its holdings in Vor Biopharma by 106.1% during the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after acquiring an additional 26,535 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock worth $61,000 after acquiring an additional 58,247 shares during the last quarter. OMERS ADMINISTRATION Corp purchased a new stake in shares of Vor Biopharma in the first quarter valued at about $100,000. Finally, Jane Street Group LLC acquired a new stake in shares of Vor Biopharma in the first quarter valued at approximately $140,000. Institutional investors and hedge funds own 97.29% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Wall Street Zen downgraded Vor Biopharma to a "strong sell" rating in a report on Saturday, June 28th. Stifel Nicolaus upgraded shares of Vor Biopharma from a "hold" rating to a "buy" rating and set a $55.00 target price for the company in a research note on Wednesday, September 24th. Robert W. Baird upgraded shares of Vor Biopharma from a "neutral" rating to an "outperform" rating and boosted their price target for the stock from $20.00 to $64.00 in a research note on Wednesday. Wedbush reissued an "outperform" rating on shares of Vor Biopharma in a report on Thursday, June 26th. Finally, Baird R W raised Vor Biopharma from a "hold" rating to a "strong-buy" rating in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $77.83.

Vor Biopharma Company Profile

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.